Mumbai, July 22, 2025:
Veerhealth Care Limited (BSE: 511523) has announced that it has received fresh export orders following its successful USFDA approval dated May 16, 2025. The company has already executed three full-container-load (FCL) shipments and plans to dispatch four to five shipments monthly to the US client, starting within the next 30 days.

This development marks a significant expansion of the company’s global operations and is expected to positively impact revenues and profitability. The company also revealed that it is in advanced discussions with a leading Russian corporate group in the oral care segment and is likely to commence exports to Russia soon.

Key Milestones & Strategic Update

Veerhealth Care, under its brand Ayuveer, focuses on natural ayurvedic oral and personal care products. Following the USFDA inspection clearance, the company began exporting to its client in the US and anticipates monthly repeat orders in the oral care category.

Commenting on the development, Bhavin Shah, Managing Director of Veerhealth Care, said:

“Securing a significant export order from a US client is a milestone for our company. This not only boosts our immediate revenue outlook but strengthens our global market presence. We are committed to long-term partnerships and expect repeat orders to become a sustainable revenue stream.”

The company has ramped up operations to full capacity to meet increased domestic and export demand, which will reduce costs and boost total income and profitability. Veerhealth expects to fully recover the dip in performance caused by the USFDA inspection delays and projects FY2025-26 revenue of ₹35–40 crore with 10% PAT.

New Division for Medical Devices and Hospital Care

Veerhealth Care is now aggressively pursuing the medical device category and is working toward regulatory formalities for exporting such products to the US. A new hospital care division has been launched in partnership with a reputed manufacturer of ventilators, infusion pumps, syringe pumps, and defibrillators, targeting government contracts and hospital supply deals.

Additionally, its plastic molding division VeerPlast focuses on high-quality toothbrush manufacturing, leveraging in-house expertise and precision technology to support its oral care expansion.

Business Segments and Capabilities

Veerhealth Care operates in the following verticals:

1. Contract Manufacturing: Manufacturing custom products for third-party brands as per client specifications.

2. White Labelling: Producing generic products sold under retailer-owned brands.

3. Research & Development: More than 100 products launched under in-house brand Ayuveer.

4. Customised Product Formulations: Specialised product development based on client specifications.

The company’s state-of-the-art facility in Vapi, Gujarat, operates under multiple certifications, including Ayurvedic GMP, Cosmetic GMP, ISO 9001:2015, and US FDA Labeler Code status.

Outlook & Financial Goals

Veerhealth is bullish about its mid-term growth, aiming to achieve ₹100 crore in revenue and a 10% PAT margin within the next 24–36 months. The combination of regulatory clearances, capacity enhancement, new international partnerships, and aggressive export expansion are expected to fuel this growth.

The company’s renewed focus on institutional supply chains, custom formulations, and global certifications positions it well in both developed and emerging markets.

About Veerhealth Care Limited

Veerhealth Care Limited (BSE: 511523) is engaged in the manufacturing and supply of Ayurvedic medicines, oral care, and personal care products under its flagship brand Ayuveer. The company caters to both domestic and export markets, with products ranging from toothpaste, shampoos, lotions, creams, and health supplements, all manufactured in its Vapi plant.

With decades of expertise led by noted ayurveda practitioners like Dr. Vinod C. Mehta and Dr. Rajiv Bhirud, the company is committed to blending ancient ayurvedic knowledge with modern quality standards.

The Upcoming IPOs in this week and coming weeks are Sellowrap Industries, Repono, Shanti Gold International, Indiqube Spaces, GNG Electronics, Brigade Hotel Ventures, Patel Chem Specialities, TSC India, NSDL.

The Current active IPO are Monarch Surveyors & Engineering Consultants, Swastika Castal, Savy Infra.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.